Tonix Pharmaceuticals Holding Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Tonix Pharmaceuticals Holding de winst en omzet met respectievelijk 27.2% en 42.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 50.9% per jaar.

Belangrijke informatie

27.2%

Groei van de winst

50.87%

Groei van de winst per aandeel

Biotechs winstgroei	25.1%
Inkomstengroei	42.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	10 Jul 2026

Recente toekomstige groei-updates

Recent updates

Seeking Alpha • Jun 29

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Summary Tonix Pharmaceuticals remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m, arguably below expectations. TNXP's cash runway is limited, with $185.5m on hand and quarterly net losses exceeding $40m, raising future funding concerns. Competitive pressure and uncertain pipeline prospects, including MDD and Lyme disease candidates, temper confidence in TNXP's ability to drive meaningful upside. I maintain a Hold, seeing limited near-term catalysts but potential upside if Tonmya sales accelerate or pipeline assets deliver unexpected positive data. Read the full article on Seeking Alpha

Analyse-artikel • Dec 01

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyse-artikel • Aug 14

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...

Winst- en omzetgroeiprognoses

NasdaqGS:TNXP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	163	-85	-170	-137	4
12/31/2027	79	-152	-205	-152	4
12/31/2026	34	-170	-200	-144	4
3/31/2026	18	-147	-131	-126	N/A
12/31/2025	13	-124	-103	-100	N/A
9/30/2025	10	-99	-76	-75	N/A
6/30/2025	10	-81	-65	-65	N/A
3/31/2025	10	-132	-60	-60	N/A
12/31/2024	10	-130	-61	-61	N/A
9/30/2024	11	-135	-69	-69	N/A
6/30/2024	12	-149	-76	-73	N/A
3/31/2024	10	-99	-91	-87	N/A
12/31/2023	8	-117	-110	-102	N/A
9/30/2023	4	-123	-114	-102	N/A
6/30/2023	N/A	-124	-121	-102	N/A
3/31/2023	N/A	-123	-132	-100	N/A
12/31/2022	N/A	-117	-146	-98	N/A
9/30/2022	N/A	-112	-167	-98	N/A
6/30/2022	N/A	-102	-156	-88	N/A
3/31/2022	N/A	-98	-141	-86	N/A
12/31/2021	N/A	-92	-111	-76	N/A
9/30/2021	N/A	-80	-81	-67	N/A
6/30/2021	N/A	-73	-80	-69	N/A
3/31/2021	N/A	-64	-69	-60	N/A
12/31/2020	N/A	-52	-57	-49	N/A
9/30/2020	N/A	-46	-45	-41	N/A
6/30/2020	N/A	-42	-33	-33	N/A
3/31/2020	N/A	-34	-27	-27	N/A
12/31/2019	N/A	-31	N/A	-27	N/A
9/30/2019	N/A	-31	N/A	-27	N/A
6/30/2019	N/A	-28	N/A	-25	N/A
3/31/2019	N/A	-29	N/A	-26	N/A
12/31/2018	N/A	-29	N/A	-24	N/A
9/30/2018	N/A	-24	N/A	-22	N/A
6/30/2018	N/A	-24	N/A	-22	N/A
3/31/2018	N/A	-23	N/A	-21	N/A
12/31/2017	N/A	-21	N/A	-19	N/A
9/30/2017	N/A	-23	N/A	-20	N/A
6/30/2017	N/A	-25	N/A	-23	N/A
3/31/2017	N/A	-30	N/A	-27	N/A
12/31/2016	N/A	-39	N/A	-37	N/A
9/30/2016	N/A	-45	N/A	-44	N/A
6/30/2016	N/A	-50	N/A	-48	N/A
3/31/2016	N/A	-52	N/A	-49	N/A
12/31/2015	N/A	-48	N/A	-43	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat TNXP de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat TNXP de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat TNXP de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van TNXP ( 42.7% per jaar) zal naar verwachting sneller groeien dan de markt US ( 13% per jaar).

Hoge groei-inkomsten: De omzet van TNXP ( 42.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van TNXP naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/07/13 18:55
Aandelenkoers aan het einde van de dag	2026/07/10 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Tonix Pharmaceuticals Holding Corp. wordt gevolgd door 11 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
James Molloy	Alliance Global Partners
Chiara Russo	Brean Capital Historical (Janney Montgomery)
David Buck	B. Riley Securities, Inc.

Tonix Pharmaceuticals Holding Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 58%

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

Forecast to breakeven in 2028

Price target decreased by 20% to US$54.33

Consensus EPS estimates upgraded to US$13.03 loss

Recent updates

Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage

Tonix Pharmaceuticals Enrolls First Patient in Phase 2 Study for Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Co-Founder recently bought US$59k worth of stock

Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody

Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment

Consensus revenue estimates decrease by 58%

New minor risk - Share price stability

New minor risk - Profitability

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

New minor risk - Profitability

Tonix Pharmaceuticals Holding Corp. Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of Tnx-4800

Co-Founder recently bought US$63k worth of stock

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease

Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900

Forecast to breakeven in 2028

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 07, 2026

Co-Founder recently bought US$223k worth of stock

Price target decreased by 20% to US$54.33

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Tonix Pharmaceuticals Presents Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Tonix Pharmaceuticals Holding Corp Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp. Presents Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) At the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals Holding Corp. Announces Program Updates on Tnx-4800 Product Candidate for Protection Against Lyme Disease

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $19.999998 million.

Tonix Pharmaceuticals Holding Corp. Appoints Irina Ishak as General Counsel, Effective December 8, 2025

Consensus EPS estimates upgraded to US$13.03 loss

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (Cybobenzaprine HCl Sublingual Tablets) as A First-In-Class Fibromyalgia Treatment

Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Tonix Pharmaceuticals Holding Corp. Presents Data on Tonmya at the 2025 American College of Rheumatology Convergence

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Tonix Pharmaceuticals Holding Corp. Presents Data on TNX-801 Mpox Vaccine at World Vaccine Congress-Europe 2025

Tonix Pharmaceuticals Holding Corp. Appoints Ganesh Kamath as Head of Market Access, Effective September 29, 2025

Tonix Pharmaceuticals Holding Corp. Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of Tnx-2900 (Intranasal Potentiated Oxytocin) in 2026

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Presents Clinical Data on Tonmya for the Treatment of Fibromyalgia at PAINWEEK 2025

Tonix Pharmaceuticals Holding Corp. Announces FDA Approval of Tonmya (cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Fibromyalgia

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Tonix Pharmaceuticals Holding Corp. to Report Q2, 2025 Results on Aug 11, 2025

Tonix Pharmaceuticals Holding Corp. Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Holding Corp. Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

High number of new directors

Tonix Pharmaceuticals Holding Corp. Appoints James ‘Jim’ Hunter to Board of Directors, Effective June 12, 2025

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates increase by 15%

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in Phase 2 Oasis Study of TNX-102 SL for Reduction of Acute Stress Response

Consensus EPS estimates upgraded to US$12.40 loss, revenue downgraded

Co-Founder recently bought US$86k worth of stock

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 88% to US$60.00

Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Washington 2025

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia At the American Academy of Pain Medicine 2025 Annual Meeting

Tonix Pharmaceuticals Holding Corp. Launches Tonix One™, A Fully-Integrated Digital Platform Designed to Help Patients Better Understanding and Manage Their Migraine Condition

Tonix Pharmaceuticals Holding Corp. Announces U.S. Food and Drug Administration to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of Tnx-102 Sl Treatment Effects on Fibromyalgia At 7Th International Congress on Cont Cont Cont Cont Cont Cont Contconties in Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Provides Earnings Guidance for the Full Year Ended December 31, 2024

Tonix Pharmaceuticals Holding Corp. Announces Positive Topline Results from Phase 1 Trial for TNX-1500, Next Generation Anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Tonix Pharmaceuticals Holding Corp. Announces Promotion of Siobhan Fogarty to Chief Technical Officer

Tonix Pharmaceuticals Holding Corp. Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia